JudithK.WolfMD

PubMed

• Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
  Lingegowda S. Mangala, Vesna Zuzel, Rosemarie Schmandt, Erik S. Leshane, Jyotsna B. Halder, Guillermo N. Armaiz-Pena, Whitney A. Spannuth, Takemi Tanaka, Mian M.K. Sha...> ;Clinical Cancer Research. 2021 Aug 1
• 2 citations
  Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer
  Anca Chelariu-Raicu, Charles F Levenback, Brian M. Slomovitz, Judith K. Wolf, Diane C. Bodurka, John J. Kavanagh, Christopher Morrison, David M. Gershenson, Robert L. ...> ;International Journal of Gynecological Cancer. 2020 Oct 9
• 2 citations
  Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.
  Brian M. Slomovitz, Anca Chelariu-Raicu, Kathleen M. Schmeler, Karen H. Lu, David M. Gershenson, Judith K. Wolf, Robert L. Coleman> ;International Journal of Gynecological Cancer. 2020 Oct 5
• 14 citations
  A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
  Meredith C. Henderson, Michael Silver, Quynh Tran, Elias Letsios, Rao Mulpuri, David E. Reese, Ana Lourenço, Joshua LaBaer, Karen S. Anderson, Josie Alpers, Carrie Cos...> ;Clinical Cancer Research. 2019 Jan 1
• 5 citations
  Breast density does not impact the ability of Videssa® Breast to detect breast cancer in women under age 50.
  David E. Reese, Meredith C. Henderson, Michael Silver, Rao Mulpuri, Elias Letsios, Quynh T. Tran, Judith K. Wolf> ;Plos One. 2017 Oct 25
• 77 citations
  Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.
  Robert L. Coleman, Thomas J. Herzog, Daniel W. Chan, Donald G. Munroe, Todd C. Pappas, Alan D. Smith, Zhen Zhang, Judith K. Wolf> ;American Journal of Obstetrics and Gynecology. 2016 Jul 1
• 3 citations
  The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients
  Ramez N. Eskander, Brian A Carpenter, Howard G Wu, Judith K. Wolf> ;Current Medical Research and Opinion. 2016 Apr 20
• 28 citations
  An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation.
  Judith K. Wolf, K. Müller-Decker, Christa Flechtenmacher, Fahao Zhang, Maria Shahmoradgoli, Gordon B. Mills, Joerg Hoheisel, Michael Boettcher> ;Oncogene. 2014 Aug 14
• Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
  Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Holstein A, Maintz D, Büttner R, Wolf J> ;Lung Cancer. 2013-07-01
• 2 citations
  Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern
  Jeannelyn S. Estrella, Judith K. Wolf, Michael T. Deavers> ;Archives of Pathology & Laboratory Medicine. 2013 Jan 31
• 4 citations
  Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.
  Justin M. Julius, Janos L. Tanyi, Graciela M. Nogueras-Gonzalez, Jack L. Watkins, Robert L. Coleman, Judith K. Wolf, Judith A. Smith> ;International Journal of Gynecological Cancer. 2013 Feb 1
• [Personalised treatment of lung cancer].
  Ullrich RT, Zander T, Wolf J, Hallek M> ;Dtsch. Med. Wochenschr.. 2012-10-01
• 51 citations
  Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
  Siqing Fu, Bryan T. Hennessy, Chaan S. Ng, Zhenlin Ju, Kevin R. Coombes, Judith K. Wolf, Anil K. Sood, Charles F Levenback, Robert L. Coleman, John J. Kavanagh, David ...> ;Gynecologic Oncology. 2012 Jul 1
• 72 citations
  A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence ris...
  Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta Szajnik, Eva Wieckowski, Sarah Bernstein, V. E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, Will...> ;Cancer Immunology, Immunotherapy. 2012 Mar 1
• 81 citations
  The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated with Differentiation and Survival in Ovarian Cancer
  Erin R. King, Celestine S. Tung, Yvonne T.M. Tsang, Zhifei Zu, Gabriel T M Lok, Michael T. Deavers, Anais Malpica, Judith K. Wolf, Karen H. Lu, Michael J. Birrer, Samu...> ;The American Journal of Surgical Pathology. 2011 Jun 1
• The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer.
  Meyer LA, Slomovitz BM, Djordjevic B, Galbincea JM, Johnston TA, Munsell M, Burzawa JK, Huang M, Broaddus R, Iglesias DA, Coleman RL, Gershenson DM, Burke TW, Wolf J, ...> ;J. Clin. Oncol.. 2011-05-20
• A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
  Slomovitz BM, Brown J, Johnston TA, Mura D, Levenback C, Wolf J, Adler KR, Lu KH, Coleman RL> ;J. Clin. Oncol.. 2011-05-20
• The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study.
  Nogova L, Mattonet C, Scheffler M, Papachristou I, Muthen N, Sos M, Hacker UT, Elter T, Backes H, Kobe C, Rhiem K, Mallmann P, Fuhr U, Schnell R, Katay I, Toepelt K, R...> ;J. Clin. Oncol.. 2011-05-20
• [18F]fluoro-L-thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced non-small cell lung cancer (NSCLC)...
  Scheffler M, Zander T, Nogova L, Kobe C, Kahraman D, Dietlein M, Papachristou I, Querings S, Stoelben E, Engel-Riedel W, Neumaier B, Wolf J> ;J. Clin. Oncol.. 2011-05-20
• 132 citations
  Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithe...
  Siqing Fu, Wei Hu, Revathy B. Iyer, John J. Kavanagh, Robert L. Coleman, Charles F Levenback, Anil K. Sood, Judith K. Wolf, David M. Gershenson, Maurie Markman, Bryan ...> ;Cancer. 2011 Apr 15
• Autologous hematopoietic cell transplantation for high-risk ALL.
  Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R> ;Bone Marrow Transplant.. 2011-03-01
• Reply to combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: Results of a prospective phase 2 trial.
  Brown, J., Wolf, J.K., Smith, J.A.> ;Cancer. 2011-02-01
• 188 citations
  A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
  Brian M. Slomovitz, Karen H. Lu, T. Johnston, Robert L. Coleman, Mark F. Munsell, Russell Broaddus, Cheryl L. Walker, Lois M. Ramondetta, Thomas W. Burke, David M. Ger...> ;Cancer. 2010 Dec 1
• Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithe...
  Fu, S., Hu, W., Iyer, R., Kavanagh, J.J., Coleman, R.L., Levenback, C.F., Sood, A.K., Wolf, J.K., Gershenson, D.M., Markman, M., Hennessy, B.T., Kurzrock, R., Bast, R.C.> ;Cancer. 2010-11-08
• 155 citations
  BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
  Kwong Kwok Wong, Yvonne T.M. Tsang, Michael T. Deavers, Samuel C. Mok, Zhifei Zu, Charlotte C. Sun, Anais Malpica, Judith K. Wolf, Karen H. Lu, David M. Gershenson> ;The American Journal of Pathology. 2010 Oct 1
• Join now to see all